Success Story: EB1A Approval in 17 Days for a Scientist Advancing Preclinical Immunology
Client’s Testimonial:
"I truly appreciate your support throughout this process.”
On March 16th, 2026, we received another EB-1A (Alien of Extraordinary Ability) approval for a Research Fellow in the Field of Immunology (Approval Notice).
General Field: Immunology
Position at the Time of Case Filing: Research Fellow
Country of Origin: South Korea
State of Residence at the Time of Filing: Maryland
Approval Notice Date: March 16th, 2026
Processing Time: 17 days (Premium Processing Requested)
Case Summary:
Before a therapy can help patients, it must first survive the uncertainty of preclinical research. That stage depends on something easy to overlook but essential to medical progress: whether the models scientists use actually reflect how biology works. In this EB1A case, North America Immigration Law Group (Chen Immigration Law Associates) represented a researcher whose career has helped make that foundation stronger.
Building Better Starting Points for Medical Innovation
Our client’s work in immunology centered on questions that shape how diseases are studied long before treatments reach clinical use. His research spanned tumor immunology, viral immunology, and host-microbiota interactions, with a particularly important focus on improving the biological relevance of preclinical systems. His work helped reveal how microbial and physiological context can fundamentally alter disease mechanisms and therapeutic interpretation.
A recommendation letter captured that importance with clarity: “His approach therefore strengthens the reliability of preclinical testing and supports medical innovation that holds direct relevance to United States research priorities and public health objectives.” That statement spoke to a central strength of the case. His contributions were valuable not only because they produced new findings, but because they improved the scientific groundwork on which later discoveries depend.
A Record That Reached the Top of the Field
The evidence showed that his standing was not confined to one niche of immunology. He had documented his work in 13 peer-reviewed journal articles, including 3 first-authored papers, with publications in leading journals. His published work had been cited 683 times, and the petition explained that this placed him among the top 1% most highly cited authors publishing on immunopathology topics over the past 7 years. At least 6 of his papers ranked among the most highly cited Immunology articles for their publication years, including several in the top 1% or top 10%.
Recognition That Could Not Be Overlooked
The case also demonstrated trust from the field itself. Our client had completed at least 10 reviews for respected journals. He also served on the editorial board and reviewer boards of some journals. These roles mattered because they showed that other experts were not simply reading his work. They were relying on his judgment to help evaluate and shape the direction of scientific publication.
His research had also attracted major funding support, including from the National Institutes of Health, the National Institute of Diabetes and Digestive and Kidney Diseases, the National Cancer Institute, the National Institute of Allergy and Infectious Diseases, and the National Research Foundation of Korea. This serves as another objective signal that his work carried recognized scientific and public health value.
The Result
This EB1A approval came from telling a persuasive story about scientific influence at the highest level. The case showed a researcher whose work had improved preclinical immunology, earned publication in elite journals, drawn extensive citation reliance, and secured the trust of other experts through peer review, editorial service, and major funding support. By weaving those elements into one coherent narrative, we demonstrated that our client had already achieved the kind of distinction EB1A is meant to recognize.